New ATAI Life Sciences-DemeRx Joint Venture Seeks To Combat Opioid Use Disorder With Ibogaine

In 2018, 2.1 million Americans met the diagnostic criteria for opioid use disorder (OUD), with 47,600 people dying from overdoses. Current treatment options for OUD are not only limited, but often carry risk of significant side effects and abuse potential.

In response to this huge unmet medical need, ATAI Life Sciences and DemeRx have announced a joint venture aimed at developing ibogaine for those suffering from opioid addiction.

Ibogaine use traces back to ancient coming-of-age ...

Continue Reading →

$22 Million Joint Venture To Purse Neurochemical Reset For Addiction

A joint venture has been set up by ATAI Life Sciences and DemeRX to develop a one and done treatment that will work to give people suffering from addiction a neurochemical reset of sorts using a drug derived from a Western African plant. 

The $22 million investment from ATAI will develop the drug ibogaine which is derived from the iboga plant that has previously been sold as a stimulant ...

Continue Reading →
Page 2 of 33 12345...»
UA-77446339-1